Budesonide (Jorveza®)

Assessment Status Rapid Review complete
Drug Budesonide
Brand Jorveza®
Indication Treatment of eosinophilic esophagitis (EoE) in adults (older than 18 years of age).
Assessment Process
Rapid review commissioned 04/12/2018
Rapid review completed 28/01/2019
Rapid review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of budesonide orodispersible tablet compared with the current standard of care, on the basis of the proposed price relative to currently available therapies.
Full pharmacoeconomic assessment commissioned by HSE 30/01/2019
Pre-submission consultation with Applicant 26/05/2020

The company has not submitted a HTA dossier to the NCPE therefore the cost effectiveness of the technology could not be proven.